Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 137

1.

Intestinal T-cell lymphoma with enteropathy-associated T-cell lymphoma-like features arising in the setting of adult autoimmune enteropathy.

Ciccocioppo R, Croci GA, Biagi F, Vanoli A, Alvisi C, Cavenaghi G, Riboni R, Arra M, Gobbi PG, Paulli M, Corazza GR.

Hematol Oncol. 2018 Apr;36(2):481-488. doi: 10.1002/hon.2494. Epub 2018 Feb 14.

PMID:
29446107
2.

Long-Term Results of the HD2000 Trial Comparing ABVD Versus BEACOPP Versus COPP-EBV-CAD in Untreated Patients With Advanced Hodgkin Lymphoma: A Study by Fondazione Italiana Linfomi.

Merli F, Luminari S, Gobbi PG, Cascavilla N, Mammi C, Ilariucci F, Stelitano C, Musso M, Baldini L, Galimberti S, Angrilli F, Polimeno G, Scalzulli PR, Ferrari A, Marcheselli L, Federico M.

J Clin Oncol. 2016 Apr 10;34(11):1175-81. doi: 10.1200/JCO.2015.62.4817. Epub 2015 Dec 28.

PMID:
26712220
3.

The Prognosis of Patients with Liver Metastases from Colorectal Cancer still Depends on Anatomical Presentation more than on Treatments.

Gobbi PG, Rossi S, Comelli M, Ravetta V, Rosa LL, Brugnatelli S, Corbella F, Delfanti S, Abumalouh I, Dionigi P.

Curr Cancer Drug Targets. 2015;15(6):511-8.

PMID:
26282549
4.

Absolute Monocyte Count and Lymphocyte-Monocyte Ratio Predict Outcome in Nodular Sclerosis Hodgkin Lymphoma: Evaluation Based on Data From 1450 Patients.

Tadmor T, Bari A, Marcheselli L, Sacchi S, Aviv A, Baldini L, Gobbi PG, Pozzi S, Ferri P, Cox MC, Cascavilla N, Iannitto E, Federico M, Polliack A.

Mayo Clin Proc. 2015 Jun;90(6):756-64. doi: 10.1016/j.mayocp.2015.03.025.

5.

Long-Term Follow-Up of Crohn Disease Fistulas After Local Injections of Bone Marrow-Derived Mesenchymal Stem Cells.

Ciccocioppo R, Gallia A, Sgarella A, Kruzliak P, Gobbi PG, Corazza GR.

Mayo Clin Proc. 2015 Jun;90(6):747-55. doi: 10.1016/j.mayocp.2015.03.023.

PMID:
26046409
6.

Metabolic tumour volumes measured at staging in lymphoma: methodological evaluation on phantom experiments and patients.

Meignan M, Sasanelli M, Casasnovas RO, Luminari S, Fioroni F, Coriani C, Masset H, Itti E, Gobbi PG, Merli F, Versari A.

Eur J Nucl Med Mol Imaging. 2014 Jun;41(6):1113-22. doi: 10.1007/s00259-014-2705-y. Epub 2014 Feb 26.

PMID:
24570094
7.

Tumor burden in Hodgkin's lymphoma: much more than the best prognostic factor.

Gobbi PG.

Crit Rev Oncol Hematol. 2014 Apr;90(1):17-23. doi: 10.1016/j.critrevonc.2013.11.002. Epub 2013 Nov 15. Review.

PMID:
24290380
8.

The prognostic role of time to diagnosis and presenting symptoms in patients with pancreatic cancer.

Gobbi PG, Bergonzi M, Comelli M, Villano L, Pozzoli D, Vanoli A, Dionigi P.

Cancer Epidemiol. 2013 Apr;37(2):186-90. doi: 10.1016/j.canep.2012.12.002. Epub 2013 Jan 29.

PMID:
23369450
9.

Tumour burden at diagnosis as the main clinical predictor of cell resistance in patients with early stage, favourable Hodgkin lymphoma treated with VBM chemotherapy plus radiotherapy.

Gobbi PG, Bergonzi M, Bassi E, Merli F, Coriani C, Federico M.

Hematol Oncol. 2013 Sep;31(3):151-5. doi: 10.1002/hon.2035. Epub 2012 Oct 29.

PMID:
23108910
10.

Hodgkin lymphoma.

Gobbi PG, Ferreri AJ, Ponzoni M, Levis A.

Crit Rev Oncol Hematol. 2013 Feb;85(2):216-37. doi: 10.1016/j.critrevonc.2012.07.002. Epub 2012 Aug 4. Review.

PMID:
22867814
11.

Tumor burden in Hodgkin's lymphoma can be reliably estimated from a few staging parameters.

Gobbi PG, Bergonzi M, Bassi E, Merli F, Coriani C, Stelitano C, Iannitto E, Federico M.

Oncol Rep. 2012 Sep;28(3):815-20. doi: 10.3892/or.2012.1892. Epub 2012 Jun 29.

PMID:
22752083
12.

How I treat enteropathy-associated T-cell lymphoma.

Di Sabatino A, Biagi F, Gobbi PG, Corazza GR.

Blood. 2012 Mar 15;119(11):2458-68. doi: 10.1182/blood-2011-10-385559. Epub 2012 Jan 23.

13.

Tumour burden predicts treatment resistance in patients with early unfavourable or advanced stage Hodgkin lymphoma treated with ABVD and radiotherapy.

Gobbi PG, Bassi E, Bergonzi M, Merli F, Coriani C, Iannitto E, Luminari S, Polimeno G, Federico M.

Hematol Oncol. 2012 Dec;30(4):194-9. doi: 10.1002/hon.1024. Epub 2012 Jan 23.

PMID:
22271092
14.

Cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab versus epirubicin, cyclophosphamide, vinblastine, prednisone and rituximab for the initial treatment of elderly "fit" patients with diffuse large B-cell lymphoma: results from the ANZINTER3 trial of the Intergruppo Italiano Linfomi.

Merli F, Luminari S, Rossi G, Mammi C, Marcheselli L, Tucci A, Ilariucci F, Chiappella A, Musso M, Di Rocco A, Stelitano C, Alvarez I, Baldini L, Mazza P, Salvi F, Arcari A, Fragasso A, Gobbi PG, Liberati AM, Federico M.

Leuk Lymphoma. 2012 Apr;53(4):581-8. doi: 10.3109/10428194.2011.621565. Epub 2011 Nov 15.

PMID:
21895543
15.

Chemoresistance as a function of the pretherapy tumor burden and the chemotherapy regimen administered: differences observed with 2 current chemotherapy regimens for advanced Hodgkin lymphoma.

Gobbi PG, Valentino F, Bassi E, Coriani C, Merli F, Bonfante V, Marchianò A, Gallamini A, Bolis S, Stelitano C, Levis A, Federico M, Angrilli F, Di Giulio G, Corazza GR.

Clin Lymphoma Myeloma Leuk. 2011 Oct;11(5):396-402. doi: 10.1016/j.clml.2011.04.008. Epub 2011 Jun 12.

PMID:
21729691
16.

What has happened to VBM (vinblastine, bleomycin, and methotrexate) chemotherapy for early-stage Hodgkin lymphoma?

Gobbi PG, Federico M.

Crit Rev Oncol Hematol. 2012 Apr;82(1):18-24. doi: 10.1016/j.critrevonc.2011.04.003. Epub 2011 May 17. Review.

PMID:
21592816
17.

Tumors of the gastroesophageal junction have intermediate prognosis compared to tumors of the esophagus and stomach, but share the same clinical determinants.

Gobbi PG, Bergonzi M, Pozzoli D, Villano L, Vanoli A, Corbella F, Dionigi P, Corazza GR.

Oncol Lett. 2011 May;2(3):503-507. Epub 2011 Mar 21.

18.

Prolonged survival in advanced thymoma: Effectiveness of sequential multiple lines of chemotherapy in an inoperable case.

Bergonzi M, Orlandoni G, Corbella F, Gobbi PG.

Oncol Lett. 2011 May;2(3):499-502. Epub 2011 Mar 21.

19.

Improving the AJCC/TNM classification for use in early gastric cancer.

Gobbi PG, Villano L, Pozzoli D, Bergonzi M, Vanoli A, Tava F, Dionigi P, Corazza GR.

J Gastrointest Surg. 2011 Jun;15(6):935-41. doi: 10.1007/s11605-011-1522-x. Epub 2011 Apr 12.

PMID:
21484483
20.

Pamidronate versus observation in asymptomatic myeloma: final results with long-term follow-up of a randomized study.

D'Arena G, Gobbi PG, Broglia C, Sacchi S, Quarta G, Baldini L, Iannitto E, Falcone A, Guariglia R, Pietrantuono G, Villani O, Martorelli MC, Mansueto G, Sanpaolo G, Cascavilla N, Musto P; Gimema (Gruppo Italiano Malattie Ematologiche Dell'Adulto); Multiple Myeloma Working Party; Gisl (Gruppo Italiano Studio Linfomi) Cooperative Group.

Leuk Lymphoma. 2011 May;52(5):771-5. doi: 10.3109/10428194.2011.553000. Epub 2011 Feb 8.

PMID:
21299465
21.

Role of conventional salvage multiple-drug chemotherapy in relapsed and refractory aggressive non-Hodgkin lymphomas.

Gobbi PG, Villano L, Pozzoli D, Bergonzi M.

Oncol Lett. 2010 Jul;1(4):679-683. Epub 2010 Jul 1.

22.

Long term outcome of patients with localized aggressive non-Hodgkin lymphoma treated with PROMECE-CYTABOM plus involved-field radiation therapy: a study by the Gruppo Italiano Studio Linfomi.

Mannina D, Luminari S, Dondi A, Polimeno G, Baldini L, Stelitano C, Merli F, Dell'Olio M, Gobbi PG, Giglio G, Barbolini E, Brugiatelli M, Federico M.

Leuk Lymphoma. 2010 Mar;51(3):422-9. doi: 10.3109/10428190903518352.

PMID:
20038237
23.

The early- and intermediate-term toxicity to primitive hematopoietic progenitor cells of three chemotherapy regimens for advanced hodgkin lymphoma.

Gobbi PG, Rosti V, Valentino F, Bonetti E, Merli F, Stelitano C, Dondi A, Quarta G, Falorio S, Federico M.

Clin Lymphoma Myeloma. 2009 Dec;9(6):425-9. doi: 10.3816/CLM.2009.n.084.

PMID:
19951881
24.

Response-guided ABVD chemotherapy plus involved-field radiation therapy for intermediate-stage Hodgkin lymphoma in the pre-positron emission tomography era: a Gruppo Italiano Studio Linfomi (GISL) prospective trial.

Iannitto E, Minardi V, Gobbi PG, Calvaruso G, Tripodo C, Marcheselli L, Luminari S, Merli F, Baldini L, Stelitano C, Callea V, Petrini M, Angrilli F, Quarta G, Vallisa D, Molica S, Liardo E, Polimeno G, Brugiatelli M, Federico M.

Clin Lymphoma Myeloma. 2009 Apr;9(2):138-44. doi: 10.3816/CLM.2009.n.034.

PMID:
19406724
25.

Bone marrow stem cell damage after three different chemotherapy regimens for advanced Hodgkin's lymphoma.

Gobbi PG, Valentino F, Danova M, Morabito F, Rovati B, Mammi C, Gentile M, Merli F, Stelitano C, Luminari S, Quintana G, Iannitto E, Brugiatelli M, Federico M.

Oncol Rep. 2009 Apr;21(4):1029-35.

PMID:
19288005
26.

Classical Hodgkin's lymphoma in adults: guidelines of the Italian Society of Hematology, the Italian Society of Experimental Hematology, and the Italian Group for Bone Marrow Transplantation on initial work-up, management, and follow-up.

Brusamolino E, Bacigalupo A, Barosi G, Biti G, Gobbi PG, Levis A, Marchetti M, Santoro A, Zinzani PL, Tura S.

Haematologica. 2009 Apr;94(4):550-65. doi: 10.3324/haematol.2008.002451. Epub 2009 Mar 10.

27.

Shortened and intensified MJMA: an effective salvage therapy for relapsed and refractory lymphomas and a strong mobilizer of PBSCs.

Gobbi PG, Valentino F, Lambelet P, Perfetti V, Bergamaschi G, Girino M, Corazza GR.

Bone Marrow Transplant. 2009 Jul;44(1):19-25. doi: 10.1038/bmt.2008.421. Epub 2009 Jan 12.

PMID:
19139733
28.

ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin's lymphoma: results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial.

Federico M, Luminari S, Iannitto E, Polimeno G, Marcheselli L, Montanini A, La Sala A, Merli F, Stelitano C, Pozzi S, Scalone R, Di Renzo N, Musto P, Baldini L, Cervetti G, Angrilli F, Mazza P, Brugiatelli M, Gobbi PG; HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial.

J Clin Oncol. 2009 Feb 10;27(5):805-11. doi: 10.1200/JCO.2008.17.0910. Epub 2009 Jan 5.

PMID:
19124807
29.

Complete long-term response to radiotherapy of gastric early-stage marginal zone lymphoma resistant to both anti-Helicobacter pylori antibiotics and chemotherapy.

Gobbi PG, Corbella F, Valentino F, Bergonzi M, Sangalli C, Perfetti V, Corazza GR.

Ann Oncol. 2009 Mar;20(3):465-8. doi: 10.1093/annonc/mdn668. Epub 2008 Dec 11.

PMID:
19074214
30.

Second malignancies after treatment of diffuse large B-cell non-Hodgkin's lymphoma: a GISL cohort study.

Sacchi S, Marcheselli L, Bari A, Marcheselli R, Pozzi S, Gobbi PG, Angrilli F, Brugiatelli M, Musto P, Federico M.

Haematologica. 2008 Sep;93(9):1335-42. doi: 10.3324/haematol.12918. Epub 2008 Aug 12.

31.

Practice guidelines for the management of extranodal non-Hodgkin's lymphomas of adult non-immunodeficient patients. Part I: primary lung and mediastinal lymphomas. A project of the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation.

Zinzani PL, Martelli M, Poletti V, Vitolo U, Gobbi PG, Chisesi T, Barosi G, Ferreri AJ, Marchetti M, Pimpinelli N, Tura S; Italian Society of Hematology; Italian Society of Experimental Hematology; Italian Group for Bone Marrow Transplantation.

Haematologica. 2008 Sep;93(9):1364-71. doi: 10.3324/haematol.12742. Epub 2008 Jul 4.

32.

High-Repetition-Rate Q-Switched Diode-Pumped Nd:YAG Laser at 1.444 mum.

Agnesi A, Dell'acqua S, Pennacchio C, Reali G, Gobbi PG.

Appl Opt. 1998 Jun 20;37(18):3984-6.

PMID:
18273367
33.

Secondary malignancies after treatment for indolent non-Hodgkin's lymphoma: a 16-year follow-up study.

Sacchi S, Marcheselli L, Bari A, Marcheselli R, Pozzi S, Luminari S, Lombardo M, Buda G, Lazzaro A, Gobbi PG, Stelitano C, Morabito F, Quarta G, Brugiatelli M.

Haematologica. 2008 Mar;93(3):398-404. doi: 10.3324/haematol.12120. Epub 2008 Feb 11.

34.

New insights into the role of age and carcinoembryonic antigen in the prognosis of colorectal cancer.

Gobbi PG, Valentino F, Berardi E, Tronconi C, Brugnatelli S, Luinetti O, Moratti R, Corazza GR.

Br J Cancer. 2008 Jan 29;98(2):328-34. Epub 2007 Nov 20.

35.

Prognostic relevance of serum beta2 microglobulin in patients with follicular lymphoma treated with anthracycline-containing regimens. A GISL study.

Federico M, Guglielmi C, Luminari S, Mammi C, Marcheselli L, Gianelli U, Maiorana A, Merli F, Bellei M, Pozzi S, Stelitano C, Lazzaro A, Gobbi PG, Baldini L, Bergantini S, Fregoni V, Brugiatelli M.

Haematologica. 2007 Nov;92(11):1482-8.

36.

Bortezomib-induced paralytic ileus is a potential gastrointestinal side effect of this first-in-class anticancer proteasome inhibitor.

Perfetti V, Palladini G, Brunetti L, Sgarella A, Brugnatelli S, Gobbi PG, Corazza GR.

Eur J Gastroenterol Hepatol. 2007 Jul;19(7):599-601.

PMID:
17556909
37.

Far and near visual acuity with multifocal intraocular lenses in an optomechanical eye model with imaging capability.

Gobbi PG, Fasce F, Bozza S, Calori G, Brancato R.

J Cataract Refract Surg. 2007 Jun;33(6):1082-94.

PMID:
17531706
38.

Optomechanical eye model with imaging capabilities for objective evaluation of intraocular lenses.

Gobbi PG, Fasce F, Bozza S, Brancato R.

J Cataract Refract Surg. 2006 Apr;32(4):643-51.

PMID:
16698488
39.

The length of treatment of aggressive non-Hodgkin's lymphomas established according to the international prognostic index score: long-term results of the GISL LA03 study.

Federico M, Luminari S, Gobbi PG, Sacchi S, Di Renzo N, Lombardo M, Merli F, Baldini L, Stelitano C, Partesotti G, Polimeno G, Montanini A, Mammi C, Brugiatelli M.

Eur J Haematol. 2006 Mar;76(3):217-29.

PMID:
16451396
40.

The role of dose size in a chemotherapy regimen (ProMECE-CytaBOM) for the first-line treatment of large B-cell lymphomas: a randomized trial by the Gruppo Italiano Studio Linfomi (GISL).

Gobbi PG, Broglia C, Valentino F, Mammi C, Lombardo M, Merli F, Luminari S, Polimeno G, Riezzo A, Lambelet P, Rovati A, Corazza GR, Federico M; Gruppo Italiano Studio Linfomi.

Ann Oncol. 2006 Apr;17(4):676-82. Epub 2006 Jan 30.

PMID:
16446317
41.

MOPPEBVCAD chemotherapy with limited and conditioned radiotherapy in advanced Hodgkin's lymphoma: 10-year results, late toxicity, and second tumors.

Gobbi PG, Broglia C, Levis A, La Sala A, Valentino F, Chisesi T, Sacchi S, Corbella F, Cavanna L, Iannitto E, Pavone V, Molica S, Corazza GR, Federico M.

Clin Cancer Res. 2006 Jan 15;12(2):529-35.

42.

ABVD versus modified stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate- and advanced-stage Hodgkin's lymphoma: final results of a multicenter randomized trial by the Intergruppo Italiano Linfomi.

Gobbi PG, Levis A, Chisesi T, Broglia C, Vitolo U, Stelitano C, Pavone V, Cavanna L, Santini G, Merli F, Liberati M, Baldini L, Deliliers GL, Angelucci E, Bordonaro R, Federico M; Intergruppo Italiano Linfomi.

J Clin Oncol. 2005 Dec 20;23(36):9198-207. Epub 2005 Sep 19.

PMID:
16172458
43.

Prognostic validation of the international classification of immunoglobulin M gammopathies: a survival advantage for patients with immunoglobulin M monoclonal gammopathy of undetermined significance?

Gobbi PG, Baldini L, Broglia C, Goldaniga M, Comelli M, Morel P, Morra E, Cortelazzo S, Bettini R, Merlini G.

Clin Cancer Res. 2005 Mar 1;11(5):1786-90.

44.

The clinical value of tumor burden at diagnosis in Hodgkin lymphoma.

Gobbi PG, Broglia C, Di Giulio G, Mantelli M, Anselmo P, Merli F, Zinzani PL, Rossi G, Callea V, Iannitto E, Paulli M, Garioni L, Ascari E.

Cancer. 2004 Oct 15;101(8):1824-34.

45.

Vinblastine, bleomycin, and methotrexate chemotherapy plus irradiation for patients with early-stage, favorable Hodgkin lymphoma: the experience of the Gruppo Italiano Studio Linfomi.

Gobbi PG, Broglia C, Merli F, Dell'Olio M, Stelitano C, Iannitto E, Federico M, Bertè R, Luisi D, Molica S, Cavalli C, Dezza L, Ascari E.

Cancer. 2003 Dec 1;98(11):2393-401.

46.

Prognostic factors in symptomatic Waldenstrom's macroglobulinemia.

Merlini G, Baldini L, Broglia C, Comelli M, Goldaniga M, Palladini G, Deliliers GL, Gobbi PG.

Semin Oncol. 2003 Apr;30(2):211-5.

PMID:
12720138
47.

Lymphomatous superficial lymph nodes: limitations of physical examination for accurate staging and response assessment.

Gobbi PG, Broglia C, Carnevale Maffè G, Ruga A, Molinari E, Ascari E.

Haematologica. 2002 Nov;87(11):1151-6.

48.

Clinical and biological effects of treatment with amifostine in myelodysplastic syndromes.

Invernizzi R, Pecci A, Travaglino E, Gobbi PG, Malabarba L, Ramajoli I, Ascari E.

Br J Haematol. 2002 Jul;118(1):246-50.

PMID:
12100155
49.

ABVD versus stanford V versus MEC in unfavourable Hodgkin's lymphoma: results of a randomised trial.

Chisesi T, Federico M, Levis A, Deliliers GL, Gobbi PG, Santini G, Luminari S, Linfomi MB; Intergruppo Italiano Linfomi.

Ann Oncol. 2002;13 Suppl 1:102-6.

PMID:
12078888
50.

Concomitant effect of topical ubiquinone Q10 and vitamin E to prevent keratocyte apoptosis after excimer laser photoablation in rabbits.

Brancato R, Fiore T, Papucci L, Schiavone N, Formigli L, Orlandini SZ, Gobbi PG, Carones F, Donnini M, Lapucci A, Capaccioli S.

J Refract Surg. 2002 Mar-Apr;18(2):135-9.

PMID:
11934201

Supplemental Content

Loading ...
Support Center